Celsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 15, 2016
08 August 2016 - 10:00PM
Celsion Corporation (NASDAQ:CLSN) announced today that the Company
will host a conference call to discuss financial results for the
quarter and six-month period ended June 30, 2016 and provide an
update on its development programs for ThermoDox®, its proprietary
heat-activated liposomal encapsulation of doxorubicin and GEN-1, an
IL-12 DNA plasmid vector formulated into a nanoparticle with a
non-viral delivery system at 11:00 a.m. EDT on Monday, August 15,
2016. To participate in the call, interested parties may dial
1-877-723-9521 (Toll-Free/North America) or 1-719-325-4925
(International/Toll) and ask for the Celsion Corporation 2nd
Quarter 2016 Earnings Call (Conference Code: 3335946) to register
ten minutes before the call is scheduled to begin. The call will
also be broadcast live over the internet at www.celsion.com.
The call will be archived for replay on Monday,
August 15, 2016 and will remain available until Monday, August 29,
2016. The replay can be accessed at 1-888-203-1112 (Toll-Free/North
America) or 1-719-457-0820 (International/Toll) using Conference
Code: 3335946. An audio replay of the call will also be
available on the Company’s website, www.celsion.com, for 30 days
after 2:00 p.m. EDT on Monday, August 15, 2016.
About Celsion Corporation
Celsion is a fully-integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including directed chemotherapies, immunotherapies and RNA- or
DNA-based therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer and in Phase II development for the treatment of
recurrent chest wall breast cancer. The pipeline also
includes GEN-1, a DNA-based immunotherapy for the localized
treatment of ovarian and brain cancers. Celsion has two
platform technologies for the development of novel nucleic
acid-based immunotherapies and other anti-cancer DNA or RNA
therapies, including TheraPlas™ and TheraSilence™. For more
information on Celsion, visit our website: www.celsion.com
(CLSN-FIN).
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2024 to May 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Celsion Corporation (NASDAQ): 0 recent articles
More News Articles